Medical Researches  

Go Back   Medical Researches > LOST RESEARCHES IN SOME COUNTRIES > United Kingdom
FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
LinkBack Thread Tools Display Modes
  #1 (permalink)  
Old 03-22-2008, 05:50 AM
abcy abcy is offline
 
Join Date: Mar 2008
Posts: 72
Default Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer.

ads
PURPOSE: The purpose of this retrospective study was to determine the association and prognostic value of body mass index (BMI) at the time of initial diagnosis in patients with locally advanced breast cancer (LABC). The analysis includes the subsets of inflammatory (IBC) and noninflammatory (non-IBC LABC) breast cancer. EXPERIMENTAL DESIGN: We identified 602 patients who had LABC treated on prospective clinical trials. BMI was divided into three groups: (a) </=24.9 (normal/underweight), (b) 25.0 to 29.9 (overweight), and (c) >/=30 (obese). Kaplan-Meier product limit method was used to estimate survival outcomes. Cox proportional hazards were used to determine associations between survival and BMI and to test for an interaction between BMI and breast cancer type. RESULTS: Eighty-two percent had non-IBC LABC and 18% had IBC. Obese patients tended to have a higher incidence of IBC compared with overweight and normal/underweight groups (P = 0.01). Median follow up was 6 years for all patients. Median overall survival (OS) and recurrence-free survival (RFS) were 8.8 and 5.9 years, respectively. Patients with LABC who were obese or overweight had a significantly worse OS and RFS (P = 0.001) and a higher incidence of visceral recurrence compared with normal/underweight patients. In a multivariable model, BMI remained significantly associated with both OS and RFS for the entire cohort. The interactions between BMI and LABC subsets and between BMI and menopausal status were not statistically significant. CONCLUSION: Patients with LABC and high BMI have a worse prognosis. Evaluation of the biological factors associated with this observation can provide tools for additional therapeutic interventions.

Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi GN, Cristofanilli M.

Authors’ Affiliations: Department of Breast Medical Oncology and Division of Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, Texas and Medical Oncology, Department of Health and Medical Services, Dubai Hospital, Dubai, United Arab Emirates.
ads
Reply With Quote
Reply


Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are On


Böcek ilaçlama , yurt ,
All times are GMT. The time now is 09:31 PM.


Powered by vBulletin® Version 3.6.8
Copyright ©2000 - 2008, Jelsoft Enterprises Ltd.
SEO by 3.0.0

sitemap
burs , burs anadolu jet kpss , , anadolu jet ,
34 35 36 37 39 40 44 46 47 48 49 50 51 52 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68